JZL195
JZL195 is a chemical compound that acts as a potent and selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH). FAAH is responsible for the degradation of endocannabinoids, such as anandamide, which are involved in various physiological processes including pain, mood, and appetite regulation.
Chemical Properties[edit | edit source]
JZL195 is characterized by its specific inhibition of FAAH, which leads to increased levels of endocannabinoids in the body. This compound has been studied for its potential therapeutic applications in conditions such as chronic pain, anxiety, and neurodegenerative diseases.
Mechanism of Action[edit | edit source]
JZL195 inhibits FAAH by binding to the active site of the enzyme, preventing it from breaking down endocannabinoids. This results in elevated levels of anandamide and other endocannabinoids, which can then activate cannabinoid receptors (CB1 and CB2) throughout the body. Activation of these receptors has been shown to produce analgesic, anti-inflammatory, and neuroprotective effects.
Therapeutic Potential[edit | edit source]
Research on JZL195 has shown promise in several areas:
- Pain Management: By inhibiting FAAH, JZL195 increases endocannabinoid levels, which can help alleviate chronic pain.
- Anxiety Disorders: Elevated endocannabinoid levels have been associated with reduced anxiety, making JZL195 a potential treatment for anxiety disorders.
- Neuroprotection: The neuroprotective effects of endocannabinoids suggest that JZL195 could be beneficial in treating neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.
Side Effects and Safety[edit | edit source]
As with any pharmacological agent, the safety profile of JZL195 is an important consideration. Studies have indicated that while JZL195 is effective in increasing endocannabinoid levels, it may also produce side effects such as hypotension, bradycardia, and potential psychotropic effects due to the activation of CB1 receptors.
Research and Development[edit | edit source]
Ongoing research is focused on understanding the full therapeutic potential of JZL195, optimizing its efficacy, and minimizing any adverse effects. Clinical trials are necessary to determine its safety and effectiveness in humans.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD